Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot aims to slash sickle cell pain crises

NCT ID NCT03814746

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is testing whether a new drug called crizanlizumab can safely reduce the number of painful vaso-occlusive crises (VOCs) in people with sickle cell disease. It involved about 240 teens and adults who have a history of these painful episodes. Participants received either one of two doses of the drug or a placebo, in addition to their standard care, to see which was more effective at preventing crises.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE (SCD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Boston Medical Center

    Boston, Massachusetts, 02118, United States

  • Childrens Healthcare of Atlanta

    Atlanta, Georgia, 30342, United States

  • Levine Cancer Insitute Carolinas Healthcare System

    Charlotte, North Carolina, 28204, United States

  • Novartis Investigative Site

    Brussels, Brussels Capital, 1070, Belgium

  • Novartis Investigative Site

    Brussels, 1000, Belgium

  • Novartis Investigative Site

    Edegem, 2650, Belgium

  • Novartis Investigative Site

    Salvador, Estado de Bahia, 41253-190, Brazil

  • Novartis Investigative Site

    Belém, Pará, 66033 000, Brazil

  • Novartis Investigative Site

    Recife, Pernambuco, 50070-170, Brazil

  • Novartis Investigative Site

    Rio de Janeiro, Rio de Janeiro, 20211-030, Brazil

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, 90035-003, Brazil

  • Novartis Investigative Site

    Ribeirão Preto, São Paulo, 14048-900, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, 01232-010, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, 05403 000, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, 08270-070, Brazil

  • Novartis Investigative Site

    Toronto, Ontario, M5G 2C4, Canada

  • Novartis Investigative Site

    Montreal, Quebec, H2X 1R9, Canada

  • Novartis Investigative Site

    Barranquilla, Atlántico, 080020, Colombia

  • Novartis Investigative Site

    Valledupar, Cesar Department, 200001, Colombia

  • Novartis Investigative Site

    Montería, 230004, Colombia

  • Novartis Investigative Site

    Helsinki, FIN 00290, Finland

  • Novartis Investigative Site

    Créteil, 94010, France

  • Novartis Investigative Site

    Marseille, 13885, France

  • Novartis Investigative Site

    Paris, 75015, France

  • Novartis Investigative Site

    Stuttgart, Baden-Wurttemberg, 70376, Germany

  • Novartis Investigative Site

    Cologne, North Rhine-Westphalia, 50937, Germany

  • Novartis Investigative Site

    Berlin, 13353, Germany

  • Novartis Investigative Site

    Essen, 45147, Germany

  • Novartis Investigative Site

    Accra, 0437-0594, Ghana

  • Novartis Investigative Site

    Athens, 115 27, Greece

  • Novartis Investigative Site

    Pátrai, 265 04, Greece

  • Novartis Investigative Site

    Thessaloniki, 54636, Greece

  • Novartis Investigative Site

    Bhubaneswar, Odisha, 751003, India

  • Novartis Investigative Site

    Hyderabad, Telangana, 500082, India

  • Novartis Investigative Site

    Genova, GE, 16128, Italy

  • Novartis Investigative Site

    Milan, MI, 20122, Italy

  • Novartis Investigative Site

    Verona, VR, 37134, Italy

  • Novartis Investigative Site

    Naples, 80138, Italy

  • Novartis Investigative Site

    Irbid, 22110, Jordan

  • Novartis Investigative Site

    Beirut, 113-0236, Lebanon

  • Novartis Investigative Site

    Tripoli, 1434, Lebanon

  • Novartis Investigative Site

    Amsterdam, North Holland, 1105 AZ, Netherlands

  • Novartis Investigative Site

    Rotterdam, South Holland, 3015 GD, Netherlands

  • Novartis Investigative Site

    The Hague, South Holland, 2545 AA, Netherlands

  • Novartis Investigative Site

    Khoudh, 123, Oman

  • Novartis Investigative Site

    Panama City, Republica de Panama, 0801, Panama

  • Novartis Investigative Site

    Panama City, 0801, Panama

  • Novartis Investigative Site

    Soweto, Gauteng, 2013, South Africa

  • Novartis Investigative Site

    Barcelona, 08035, Spain

  • Novartis Investigative Site

    Madrid, 28034, Spain

  • Novartis Investigative Site

    Madrid, 28046, Spain

  • Novartis Investigative Site

    Adana, Saricam, 01330, Turkey (Türkiye)

  • Novartis Investigative Site

    Sheffield, South Yorkshire, S10 2JF, United Kingdom

  • Novartis Investigative Site

    Cambridge, CB2 0QQ, United Kingdom

  • Novartis Investigative Site

    London, SE1 9RT, United Kingdom

  • Novartis Investigative Site

    London, SE5 9RS, United Kingdom

  • Novartis Investigative Site

    Sheffield, S10 2TH, United Kingdom

  • U of TX Health Science Ct

    Houston, Texas, 77030, United States

  • Univ of Tenn Health Sciences Ctr

    Memphis, Tennessee, 38163, United States

Conditions

Explore the condition pages connected to this study.

SICKLE CELL DISEASE (SCD)